Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli & Guido Kroemer. (2020) Trial watch: STING agonists in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Jabeena Khazir, Bilal
Ahmad Mir, Shabir
Ahmad Mir & Don Cowan. (2013) Natural products as lead compounds in drug discovery. Journal of Asian Natural Products Research 15:7, pages 764-788.
Read now
Read now
Emmanuel S Antonarakis & Michael A Carducci. (2012) Targeting angiogenesis for the treatment of prostate cancer. Expert Opinion on Therapeutic Targets 16:4, pages 365-376.
Read now
Read now
Articles from other publishers (28)
Yiqing Cai, Xiaomin Chen, Tiange Lu, Zhuoya Yu, Shunfeng Hu, Jiarui Liu, Xiangxiang Zhou & Xin Wang. (2023) Single-cell transcriptome analysis profiles the expression features of TMEM173 in BM cells of high-risk B-cell acute lymphoblastic leukemia. BMC Cancer 23:1.
Crossref
Crossref
Tanu Kaushal, Gaurava Srivastava, Ashok Sharma & Arvind Singh Negi. (2019) An insight into medicinal chemistry of anticancer quinoxalines. Bioorganic & Medicinal Chemistry 27:1, pages 16-35.
Crossref
Crossref
Dhanya K. C.Aditya Menon & Laxmi Shanker Rai. 2019. Phytochemistry: An in-silico and in-vitro Update. Phytochemistry: An in-silico and in-vitro Update
251
265
.
Amir Daei Farshchi Adli, Rana Jahanban-Esfahlan, Khaled Seidi, Sonia Samandari-Rad & Nosratollah Zarghami. (2018) An overview on Vadimezan (DMXAA): The vascular disrupting agent. Chemical Biology & Drug Design 91:5, pages 996-1006.
Crossref
Crossref
Yi-Ju Ho, Tzu-Chia Wang, Ching-Hsiang Fan & Chih-Kuang Yeh. (2017) Current progress in antivascular tumor therapy. Drug Discovery Today 22:10, pages 1503-1515.
Crossref
Crossref
Constanze Hantel, Alexandra Ozimek, Regia Lira, Bruno Ragazzon, Carsten Jäckel, Roman Frantsev, Martin Reincke, Jérôme Bertherat, Thomas Mussack & Felix Beuschlein. (2016) TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors. Molecular and Cellular Endocrinology 423, pages 87-95.
Crossref
Crossref
Zhiyan Xiao, Susan L. Morris-Natschke & Kuo-Hsiung Lee. (2016) Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates. Medicinal Research Reviews 36:1, pages 32-91.
Crossref
Crossref
Jayanthi Eswaran, Kalaiselvi Sivalingam, Vijaya Padma Viswanatha, S.P. Bhuvanesh Nattamai & Dharmaraj Nallasamy. (2015) Synthesis, characterization, DNA/protein binding and in vitro cytotoxic evaluation of new Ru(III) complexes containing aroylhydrazone ligands: Does hydrogen bonding influence the coordination behavior of hydrazones?. Inorganica Chimica Acta 429, pages 148-159.
Crossref
Crossref
Elena Porcù, Roberta Bortolozzi, Giuseppe Basso & Giampietro Viola. (2014) Recent advances in vascular disrupting agents in cancer therapy. Future Medicinal Chemistry 6:13, pages 1485-1498.
Crossref
Crossref
Joseph Conlon, Dara L. Burdette, Shruti Sharma, Numana Bhat, Mikayla Thompson, Zhaozhao Jiang, Vijay A. K. Rathinam, Brian Monks, Tengchuan Jin, T. Sam Xiao, Stefanie N. Vogel, Russell E. Vance & Katherine A. Fitzgerald. (2013) Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid. The Journal of Immunology 190:10, pages 5216-5225.
Crossref
Crossref
David E. Goertz, Margarita Todorova, Omid Mortazavi, Vlad Agache, Branson Chen, Raffi Karshafian & Kullervo Hynynen. (2012) Antitumor Effects of Combining Docetaxel (Taxotere) with the Antivascular Action of Ultrasound Stimulated Microbubbles. PLoS ONE 7:12, pages e52307.
Crossref
Crossref
Bhuwan B. Mishra & Vinod K. Tiwari. (2011) Natural products: An evolving role in future drug discovery. European Journal of Medicinal Chemistry 46:10, pages 4769-4807.
Crossref
Crossref
Allison Marrero, Theresa Becker, Ulas Sunar, Janet Morgan & David Bellnier. (2011) Aminolevulinic Acid‐Photodynamic Therapy Combined with Topically Applied Vascular Disrupting Agent Vadimezan Leads to Enhanced Antitumor Responses. Photochemistry and Photobiology 87:4, pages 910-919.
Crossref
Crossref
Ajit S. Narang & Sailesh Varia. (2011) Role of tumor vascular architecture in drug delivery. Advanced Drug Delivery Reviews 63:8, pages 640-658.
Crossref
Crossref
Christoph Oehler, Joseph A. O'Donoghue, James Russell, Pat Zanzonico, Sylvie Lorenzen, C. Clifton Ling & Sean Carlin. (2011)
18
F-Fluromisonidazole PET Imaging as a Biomarker for the Response to 5,6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors
. Journal of Nuclear Medicine 52:3, pages 437-444.
Crossref
Crossref
Dietmar W. Siemann. (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treatment Reviews 37:1, pages 63-74.
Crossref
Crossref
Emmanuel S. Antonarakis & Michael A. Carducci. (2010) Future Directions in Castrate-Resistant Prostate Cancer Therapy. Clinical Genitourinary Cancer 8:1, pages 37-46.
Crossref
Crossref
Roberto Pili, Mark A. Rosenthal, Paul N. Mainwaring, Guy Van Hazel, Sandy Srinivas, Robert Dreicer, Sanjay Goel, Joseph Leach, Shirley Wong & Peter Clingan. (2010) Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC. Clinical Cancer Research 16:10, pages 2906-2914.
Crossref
Crossref
Emmanuel S. Antonarakis, Michael A. Carducci & Mario A. Eisenberger. (2010) Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Letters 291:1, pages 1-13.
Crossref
Crossref
Mark J. McKeage & Bruce C. Baguley. (2010) Disrupting established tumor blood vessels. Cancer 116:8, pages 1859-1871.
Crossref
Crossref
Bruce C. Baguley. 2010. Vascular Disruptive Agents for the Treatment of Cancer. Vascular Disruptive Agents for the Treatment of Cancer
217
230
.
Graeme J. Dougherty & David J. Chaplin. 2010. Vascular Disruptive Agents for the Treatment of Cancer. Vascular Disruptive Agents for the Treatment of Cancer
1
27
.
Shangjin Yang & William A. Denny. (2009) A new short synthesis of 5,6-dimethylxanthenone-4-acetic acid (ASA404, DMXAA). Tetrahedron Letters 50:27, pages 3945-3947.
Crossref
Crossref
L.-C. Steve Wang, Lai-Ming Ching, James W. Paxton, Philip Kestell, Rachel Sutherland, Li Zhuang & Bruce C. Baguley. (2008) Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. Investigational New Drugs 27:3, pages 280-284.
Crossref
Crossref
Ajit S. Narang & Divyakant S. Desai. 2009. Pharmaceutical Perspectives of Cancer Therapeutics. Pharmaceutical Perspectives of Cancer Therapeutics
49
92
.
Anne-Marie Liberatore, Hélène Coulomb, Dominique Pons, Olivier Dutruel, Philip G. Kasprzyk, Mark Carlson, Ann Savola Nelson, Simon P. Newman, Chloe Stengel, Pierrïck Auvray, Vincent Hesry, Béatrice Foll, Nadine Narboux, Delphine Morlais, Mélissa Le Moing, Sonia Bernetiere, Raphael Dellile, Jose Camara, Eric Ferrandis, Dennis C. Bigg & Grégoire P. Prévost. (2008) IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents. Molecular Cancer Therapeutics 7:8, pages 2426-2434.
Crossref
Crossref
Mark S. Butler. (2008) Natural products to drugs: natural product-derived compounds in clinical trials. Natural Product Reports 25:3, pages 475.
Crossref
Crossref
Chryso Kanthou & Gillian M. Tozer. (2007) Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton. Drug Discovery Today: Therapeutic Strategies 4:4, pages 237-243.
Crossref
Crossref